Search
Amino acids
go.drugbank.com/drugs/DB09393InvestigationalMixture of amino acids ; used for parenteral nutrition in infants.
Categories: Solutions for Parenteral NutritionFitusiran
go.drugbank.com/drugs/DB15002ApprovedInvestigationalFitusiran is an antithrombin-directed double-stranded small interfering ribonucleic acid (siRNA) that is covalently linked to a ligand containing a triantennary N-acetylgalactosamine (GalNAc) moiety. Fitusiran was first approved by the F...
BMS-564929
go.drugbank.com/drugs/DB07286ExperimentalSo far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause. … BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM).
Dihydrostreptomycin
go.drugbank.com/drugs/DB11512ApprovedVet approvedWithdrawnThe FDA withdrew its approval for the use of all drug products containing dihydrostreptomycin sulfate.[L43942]
Diethylstilbestrol
go.drugbank.com/drugs/DB00255ApprovedWithdrawn(Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.[L43942]
Categories: Hormonal Contraceptives for Systemic UseFelodipine
go.drugbank.com/drugs/DB01023ApprovedIn addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent
Categories: Antihypertensive Agents Indicated for HypertensionPirenzepine
go.drugbank.com/drugs/DB00670ApprovedWithdrawnAn antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duod...
Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)Citatuzumab Bogatox
go.drugbank.com/drugs/DB06072InvestigationalVB6-845 is a humanized antibody fragment targeting EpCAM fused with the deimmunized form of the cytotoxin Bouganin and is designed for systemic use against metastatic cancer.
Cosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalOn December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the
Categories: Programmed Death Receptor-1 Blocking AntibodyAlbinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalHuman Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C. … The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C.